ClinicalTrials.gg
TerminatedNCT00700622Updated Oct 16, 2014Results posted

Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks

A Phase 3 interventional study of Technosphere Insulin and Insulin glargine in Diabetes, Type 1, sponsored by Mannkind Corporation. Terminated at 22 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-10-16.

Sponsored by Mannkind Corporation · Phase 3, Interventional, and Treatment

Why this study was terminated
Sponsor stopped development of the MedTone inhaler in favor of an improved device (Gen2 inhaler)

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 — 1 open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 1.

Enrollment
15th of 35
130 · median 74
Started
2008
with 2 others
Phase 3
17 of 35
none open now
Registered
20th of 35
by date
Lead sponsor
14 of 35
Mannkind Corporation

Among the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, this one is the 15th largest by enrollment, is one of 3 that started in 2008, is one of 17 in phase 3, and was the 20th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

1 of the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Insulin, Regular, Human

Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

The objective of this study is to demonstrate that TI® Inhalation Powder combined with Lantus® is as effective as Humalog® combined with Lantus® on HbA1c.

03

Conditions studied

  • Diabetes, Type 1
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women ≥ 18 and ≤ 80 years old
  • Clinical diagnosis of type 1 diabetes mellitus for more than 12 months
  • (BMI) ≤ 30 kg/m2
  • Stable antidiabetic regimen of sc insulin therapy at a total daily dose ≤ 1.5 IU/kg/day
  • > 7.0% and ≤ 9.0%
  • C-peptide level ≤ 0.30 pmol/mL
  • Nonsmokers (includes cigarettes, cigars, pipes, and chewing tobacco) for at least the preceding 6 months
  • Negative urine cotinine defined as ≤ 100 ng/mL
  • Pulmonary function tests (PFTs):

    • (FEV1) ≥ 70% Third National Health and Nutrition Examination Survey (NHANES III) predicted
    • FEV1 as a percentage of FEV1/forced vital capacity (FVC) ≥ 70% (NHANES III) predicted
    • Total lung capacity (TLC) ≥ 80% predicted (Intermountain Thoracic Society [ITS])
    • Single breath carbon monoxide diffusing capacity of the lung, -corrected (DLco-Hb) (uncorrected) ≥ 70% predicted
  • For the subset of subjects having Doppler echocardiograms: right ventricular systolic pressure (RVSP) ≤ 40 mm Hg at Visit 1
  • Written

Exclusion criteria

Exclusion Criteria:

  • Treatment with any type of antidiabetic drugs, other than sc insulin, within the preceding 12 weeks
  • Two or more severe hypoglycemic episodes within 6 months of screening or episode of severe hypoglycemia between Visit 1 and Visit 5
  • Any hospitalization or emergency room visit due to poor diabetic control within 6 months of Visit 1, or hospitalization or emergency room visit due to poor diabetic control between Visit 1 and Visit 5
  • Severe complications of diabetes, in the opinion of the PI, including symptomatic autonomic neuropathy; disabling peripheral neuropathy; active proliferative retinopathy; nephropathy with renal failure, renal transplant, or dialysis; history of foot ulcers; nontraumatic amputations due to gangrene; or vascular claudication
  • Previous exposure to an inhaled insulin product within 3 months of Visit 1
  • History of insulin pump use within 6 weeks of Visit 1
  • Allergy or known to insulin or to any of the drugs to be used in the trial, or a history of hypersensitivity to TI Inhalation Powder or to drugs with a similar chemical structure
  • Significant improvement in pre- to postbronchodilator spirometry at Visit 1 (defined as an increase of 12% and 200 mL in either or FVC)
  • History of (COPD), clinically proven asthma, or any other pulmonary disease (eg, obstructive sleep apnea) confirmed by pulmonary function testing or radiologic findings
  • Inability to perform spirometry maneuvers meeting recommended American Thoracic Society (ATS) standards of acceptability and repeatability criteria
  • Active respiratory infection (subject could return after 30 days from resolution for rescreening); if respiratory infection manifested after Visit 1 but before Visit 1 PFTs, subject was to be scheduled for PFTs after 30 days from resolution of respiratory infection. An additional was to be required
  • Major organ system diseases, including:

    • Seizure disorder
    • Significant cardiovascular dysfunction or history within 3 months of Visit 1, eg, congestive heart failure ( [NYHA] Class III or IV), or serious arrhythmia, myocardial infarction, cardiac surgery, recurrent syncope, , or cerebrovascular accident
    • Uncontrolled hypertension with a systolic blood pressure > 180 mm Hg or diastolic blood pressure > 110 mm Hg at Visit 1 despite pharmacologic treatment
    • Nephrotic syndrome; renal dysfunction or disease; serum creatinine > 2.0 mg/dL (0.11 mmol/L) in men and > 1.8 mg/dL (0.1 mmol/L) in women; or blood urea nitrogen (BUN) > 50 mg/dL (2.8 mmol/L)
    • Cancer (other than excised cutaneous basal cell carcinoma) within the past 5 years or any history of lung neoplasms
    • History of active viral or cirrhotic hepatic disease or abnormal liver enzymes as evidenced by serum (AST) or alanine aminotransferase (ALT) ≥ 3 times the (ULN)
    • Active infection (eg, [HIV], hepatitis) or history of severe infection within 30 days of Visit 1
    • Anemia (hemoglobin ≤ 10.5 g/dL for women or ≤ 11.5 g/dL for men)
    • Diagnosis of systemic or collagen vascular disease requiring previous or current treatment with systemic , cytotoxic drugs, or penicillamine
    • Any concurrent illness, other than diabetes mellitus, not controlled by a stable therapeutic regimen
  • Current or previous chemotherapy or radiation therapy that might result in pulmonary toxicity
  • Use of medications prescribed for weight loss (eg, sibutramine, orlistat) within 12 weeks of Visit 1
  • Any history of or current use of amiodarone
  • Clinically significant abnormalities on screening laboratory evaluation (unless discussed with and approved by the medical monitor)
  • Women who were pregnant, lactating, or planning to become pregnant during the trial
  • Women of (defined as premenopausal and not surgically sterilized or for fewer than 2 years) not practicing adequate . Adequate birth control was defined as using oral, percutaneous, or transdermal contraceptives; condoms and diaphragms (double barrier) with a spermicide; or intrauterine devices. Postmenopausal for this trial included amenorrhea for 2 or more years or surgically sterile
  • Current drug or alcohol abuse or a history of drug or alcohol abuse that, in the opinion of the PI, would make the subject an unsuitable candidate for participation in the trial
  • Exposure to any medications or devices within 30 days before trial entry, or participation in another clinical trial while participating in this trial
  • Unable or unlikely to comprehend and follow the trial protocol (including SBGM and diabetes education)
  • Unable or unlikely to comprehend how to use the MedTone Inhaler or inability to use the device
  • Unable or unlikely to follow a meal plan that included at least 2 meals/day (with or without a third meal or additional snacks)
  • Noncompliance with medication or procedures that, in the PI's opinion, might affect the trial data or subject safety and that precluded the subject from further participation in the trial
  • Any other concurrent medical or major psychiatric condition that, in the opinion of the PI, made the subject unsuitable for the clinical trial or could limit the validity of the or impair the subject's ability to participate in the trial
  • For the subset of subjects having Doppler echocardiograms:

    • Subjects with (LVEF) ≤ 35% at Visit 1
    • Subjects with known history of sickle cell disease
    • Previous use of Redux® (dexfenfluramine) or Pondimin® (fenfluramine)
    • History of valvular heart disease, including mild or greater aortic insufficiency or moderate or greater mitral insufficiency
    • Significant cardiovascular dysfunction or history within 12 months of Visit 1 (eg, congestive heart failure [NYHA Class III or IV]) or serious arrhythmia, treatment with medications to control or treat arrhythmias, myocardial infarction, cardiac surgery, recurrent syncope, transient ischemic attacks, or cerebrovascular accident
    • History of pulmonary embolism or deep venous thrombosis in the 12 months before Screening
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
130 participants (actual)

Study arms

  • Experimental
    TI + Insulin glargine

    Technosphere Insulin Inhalation Powder in combination with Lantus (insulin glargine)

    Drug: Technosphere Insulin

  • Experimental
    Insulin lispro + Insulin glargine

    Humalog (insulin lispro) in combination with Lantus (insulin glargine)

    Drug: Insulin glargine · Drug: Insulin lispro

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c to Week 16

    Change from Baseline in glycosylated hemoglobin at Week 16

    Time frame: Baseline to Week 16

07

Results

Posted Oct 16, 2014
Limitations and caveats
- Early termination of trial leading to small numbers of subjects analyzed.

Participant flow

The FPFV was May 30, 2008. Multinational trial conducted in the US and Brazil.

Participant flow — Overall Study
MilestoneTI + Insulin GlargineInsulin Lispro + Insulin Glargine
Started6565
Completed5260
Not completed135
Withdrew: Adverse event40
Withdrew: Lost to follow-up01
Withdrew: Physician decision21
Withdrew: Protocol violation01
Withdrew: Withdrawal by subject41
Withdrew: Other31

Outcome measures

PrimaryChange From Baseline in HbA1c to Week 16

Change from Baseline in glycosylated hemoglobin at Week 16

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · percentage of total hemoglobin
Change From Baseline in HbA1c to Week 16
percentage of total hemoglobinTI + Insulin GlargineInsulin Lispro + Insulin Glargine
Change From Baseline in HbA1c to Week 16-0.10 ± 0.087-0.03 ± 0.082
Statistical analysis
  • Insulin Lispro + Insulin Glargine · ANCOVA · Mean difference (net): -0.07 · 95% CI -0.31 to 0.17

Adverse events

Collected over SAEs: From first dose to 30d post last dose AEs: From first dose to 30d post last dose. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TI + Insulin Glargine—1/65 (1.5%)42/65 (64.6%)
Insulin Lispro + Insulin Glargine—3/65 (4.6%)34/65 (52.3%)
Most frequent serious events
Most frequent serious events
EventTI + Insulin GlargineInsulin Lispro + Insulin Glargine
HypoglycemiaMetabolism and nutrition disorders1/652/65
Delayed recovery from anesthesiaInjury, poisoning and procedural complications0/651/65
Intentional overdoseInjury, poisoning and procedural complications0/651/65
Hypoglycemic seizureMetabolism and nutrition disorders0/651/65
Suicide attemptPsychiatric disorders0/651/65
Most frequent other events
Most frequent other events
EventTI + Insulin GlargineInsulin Lispro + Insulin Glargine
CoughRespiratory, thoracic and mediastinal disorders29/650/65
HypoglycaemiaEndocrine disorders21/6523/65
InfluenzaInfections and infestations3/6511/65
Upper respiratory infectionInfections and infestations5/656/65
SinusitisInfections and infestations5/652/65
Chest discomfortGeneral disorders4/650/65
Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders4/652/65
NasopharyngitisInfections and infestations3/654/65

Baseline characteristics

Age, Continuous
Age, Continuous(years)TI + Insulin GlargineInsulin Lispro + Insulin GlargineTotal
Mean38.6 ± 11.8239.4 ± 11.4639.0 ± 11.60
Sex: Female, Male
Sex: Female, Male(Participants)TI + Insulin GlargineInsulin Lispro + Insulin GlargineTotal
Female253257
Male403373
Weight
Weight(kg)TI + Insulin GlargineInsulin Lispro + Insulin GlargineTotal
Mean74.49 ± 13.27074.18 ± 13.89474.3 ± 13.53
Height
Height(cm)TI + Insulin GlargineInsulin Lispro + Insulin GlargineTotal
Mean172.22 ± 9.238169.61 ± 9.807170.9 ± 9.579
Body Mass Index
Body Mass Index(kg/m^2)TI + Insulin GlargineInsulin Lispro + Insulin GlargineTotal
Mean25.07 ± 3.74425.63 ± 3.14125.3 ± 3.454
HbA1c
HbA1c(%)TI + Insulin GlargineInsulin Lispro + Insulin GlargineTotal
Mean7.76 ± 0.5507.62 ± 0.6027.69 ± 0.579
Waist Circumference
Waist Circumference(cm)TI + Insulin GlargineInsulin Lispro + Insulin GlargineTotal
Mean86.26 ± 10.44587.31 ± 10.66986.78 ± 10.530
Fasting Blood Glucose
Fasting Blood Glucose(mg/dL)TI + Insulin GlargineInsulin Lispro + Insulin GlargineTotal
Mean178.06 ± 76.916176.20 ± 67.268177.15 ± 72.084

1 further baseline measures are reported on the registry.

08

Study locations

22 sites
  • Diabetes/Lipid Management and Research Center
    Huntington Beach, California 92648, United States
  • The Whittier Institute for Diabetes Clinical Trials
    La Jolla, California 92037, United States
  • Dorothy L & James E Frank Diabetes Research Institute
    San Mateo, California 94401, United States
  • Barbara Davis Center for Diabetes Young Adult Clinic
    Aurora, Colorado 80045, United States
  • University of Miami Diabetes Research Institute
    Miami, Florida 33136, United States
  • University of Miami School of Medicine
    Miami, Florida 33136, United States
  • Atlanta Diabetes Associates
    Atlanta, Georgia 30309, United States
  • Tulane University Health Sciences Center
    New Orleans, Louisiana 70112-2699, United States
  • Washington University School of Medicine
    St. Louis, Missouri 63110, United States
  • Deaconess Billings Clinic Research Center
    Billings, Montana 59101, United States
  • Mountain Diabetes & Endocrine Center
    Asheville, North Carolina 28803, United States
  • Endocrine Research Physicians East PA
    Greenville, North Carolina 27834, United States
  • Your Diabetes Endocrine Nutrition Group, Inc.
    Mentor, Ohio 44060, United States
  • OHSU Diabetes Center Research Oregon Health & Science University
    Portland, Oregon 97239, United States
  • AM Diabetes and Endocrinology Center
    Barrtlett, Tennessee 38133, United States
  • Dallas Diabetes & Endocrine Center
    Dallas, Texas 75230, United States
  • Baylor Endocrine Center
    Dallas, Texas 75246, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Diabetes Research Center -Fletcher Allen Health Care
    South Burlington, Vermont 05403, United States
  • Diabetes Care Center
    Seattle, Washington 98105, United States
  • Centro de Pesquisas em Diabetes Ltda
    Porto Alegre, RS -90035-170, Brazil
  • CPClin-Centro de Pesquisas Clinicas
    Sao Paulo, 01244-030, Brazil
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Nov 2009 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 4 years 11 months after primary completion. A results delay was requested in Jun 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2008
First posted
Jun 18, 2008
Start
May 2008
Primary completionActual
Nov 2009
CompletionActual
Mar 2010
Results delay requested
Jun 9, 2009
Results first posted
Oct 16, 2014
Last update
Oct 16, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00700622
Responsible party
Sponsor
First posted
Jun 18, 2008
Start date
May 2008
Primary completion
Nov 2009
Completion
Mar 2010
Results posted
Oct 16, 2014
Last update
Oct 16, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin, Regular, Human · Insulin Glargine · Insulin Lispro

Start the discussion